Immune response modifier compounds for treatment of TH2 mediated and related diseases

Abstract

Immune response modifier compounds-imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines-are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.

We claim:  
     
       1. A method of inhibiting induction of IL-4 and/or IL-5 cytokines to treat a non-viral and non-tumor disease comprising administering an immune response modifier compound selected from the group consisting of imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines in an amount effective to inhibit said IL-4 and/or IL-5 cytokines, with the proviso that said disease is other than eczema. 
     
     
       2. The method of  claim 1 , wherein the compound is an imidazopyridine amine. 
     
     
       3. The method of  claim 1 , wherein thc compound is a 6,7-fused cycloalkylimidazopyridine amine. 
     
     
       4. The method of  claim 1 , wherein thc compound is an 1,2-bridged imidazoquinoline amine. 
     
     
       5. The method of  claim 1 ,  2 ,  3 , or  4 , wherein said disease is a parasitic infection. 
     
     
       6. The method of  claim 1 ,  2 ,  3 , or  4 , wherein said disease is a bacterial infection. 
     
     
       7. The method of  claim 1 ,  2 ,  3 , or  4 , wherein said disease is a fungal infection. 
     
     
       8. The method of  claim 1 ,  2 ,  3 , or  4 , wherein said disease is selected from the group consisting of asthma, allergy, leprosy, tuberculosis, systcmic lupus crythematosis, Ommen's syndrome, leishmaniasis, toxoplasma infection, trypanosome infection, candidiasis, and histoplasmosis. 
     
     
       9. The method of  claim 8 , wherein said disease is selected from the group consisting of asthma and allergic rhinitis. 
     
     
       10. The method of  claim 1 ,  2 ,  3 ,  4 , or  5 , wherein said compound is administered via oral or nasal inhalation. 
     
     
       11. The method of  claim 1 ,  2 ,  3 , or  4 , wherein said compound is administered via a topical cream or gel.